Pfizer Positive Data from Phase 2 Study of Ponsegromab in Cancer Cachexia

• Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at 12 weeks; ponsegromab was generally considered safe and well-tolerated at all dose levelsi
• At the highest dose evaluated, improvements were seen from baseline in appetite and cachexia symptoms, physical activity, and muscle massi
• Based on positive Phase 2 results, registration-enabling studies will start in 2025

https://www.businesswire.com/news/home/20240913347614/en/